author={Rasha Mukhtar and J. Reid and John P. D. Reckless},
  journal={Reactions Weekly},
The growing number of trials that have highlighted the benefit of intensive lowering of total‐ and low density lipoprotein (LDL)‐cholesterol levels especially with statins has created a need for more efficacious agents. Pitavastatin is a new synthetic 3‐hydroxy‐3‐methyl glutaryl coenzyme A reductase inhibitor, which was developed, and has been available in Japan since July 2003. 


Novel Statins: Pharmacological and Clinical Results
As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased cholesterol lowering potency may ensure the achievement of target cholesterol levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.
Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
Pitavastatin significantly decreased the serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) at doses of 1mg/day or more, and significant dose-dependence of the effect of this drug was observed within the dose range from 1 mg/ day to 4 mg/day.
Novel approaches to lipid lowering: what is on the horizon?
  • W. Brown
  • Biology, Chemistry
    The American journal of cardiology
  • 2001
Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
Pitavastatin is a novel, fully synthetic statin, which has a potent cholesterol-lowering action and could provide a new and potentially better therapeutic choice for lipid-modifying therapy than do the currently available statins.
NK-104: a novel synthetic HMG-CoA reductase inhibitor
Results supported the ‘lower is better’ hypothesis in the relationship between LDL-cholesterol levels and CAD and suggested NK-104 can provide a new and potentially superior therapeutic agent when compared with currently available other statins.
Pharmacology of 3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin
This article summarizes the pharmacological data of five novel statins and points out potential mechanisms leading to increased toxicity since the prevalence of adverse events can be explained at least in part by their pharmacokinetic differences.
Statins: the new aspirin?
The targets and mechanisms of action of statins are described in detail, showing that pleiotropic effects extend far beyond cholesterol reduction and involve non-lipid-related mechanisms that modify endothelial functions, immunoinflammatory responses, smooth muscle cell activation, proliferation and migration, atherosclerotic plaque stability, and thrombus formation.
Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor.
  • W. Isley
  • Biology, Chemistry
    Drugs of today
  • 2001
Early studies suggest that Pitavastatin calcium may be quite useful for treating common dyslipidemias and may produce marked reductions in triglyceride-rich particles, which are proven to have positive effects on cardiovascular risk.